期刊文献+

腋窝淋巴结阴性浸润性乳腺癌的分子分型及预后观察

Different molecular classification in the distribution of axillary lymph node negative invasive breast cancer and prognosis is seen
原文传递
导出
摘要 目的探讨腋窝淋巴结阴性浸润性乳腺癌患者的分子分型及其预后情况。方法回顾性分析2006年12月至2009年6月间180例腋窝淋巴结阴性浸润性乳腺癌的临床病理资料,并按照雌激素受体(ER)、孕激素受体(PR)及人类表皮生长因子受体-2(HER-2)的检测结果将其分为管腔上皮(Luminal)型、基底样(Basal-like)型及HER-2过表达(over-expression)型,观察不同分型乳腺癌在不同年龄、肿瘤大小及分期中的表达及预后情况。结果 180例腋窝淋巴结阴性浸润性乳腺癌患者中,Luminal型、Basal-like型、HER-2过表达型分别占54.4%(98/180)、27.8%(50/180)和17.8%(32/180)。Luminal型、Basal-like型、HER-2过表达型在不同年龄、肿瘤大小及临床分期中的表达差异无统计学意义(P>0.05)。Basal-like型患者术后36和60个月的转移率分别为14.0%和36.0%,高于Luminal型的3.1%、20.4%及HER-2过表达型的6.3%、21.9%,差异有统计学意义(P<0.05)。Basal-like型患者术后60个月的死亡率为24.0%,高于Luminal型(10.2%)及HER-2过表达型(15.6%),HER-2过表达型患者术后60个月的死亡率高于Luminal型,差异有统计学意义(P<0.05)。结论腋窝淋巴结阴性浸润性乳腺癌的分子分型以Lumina1型最为常见,Basal-like型与HER-2过表达型构成比较低,其中Basal-like型患者预后较差,其次为HER-2过表达型患者。 Objective To explore the expression of axillary lymph node-negative type of invasive breast cancer molecules and analyze prognosis. Methods A total of clinical pathological information of 180 cases with axillary lymph node negative invasive breast cancer were retrospectively analyzed, and according to the estrogen receptor (ER), progesterone receptor (PR) , and human epidermal growth factor receptor 2 ( HER2 ) test results, patients were divided into the luminal epithelium ( Luminal ), basaloid ( Basal hominins-like) and HER2 expression (over-expression) type, observed the expression of three type in different age, tumor size and staging patients with breast cancer and prognosis of them. Results ( 1 ) Luminal, Bas- al-like, HER-2 overexpression type in 180 cases of invasive breast cancer with axillary lymph node-negative was 54.4% (98/180), 27.8% (50/180), 17.8% (32/180), respectively; (2)The expression of Lu- minal, Basal-like, HER-2 overexpression type in different age, tumor size and clinical staging patients was not statistically difference ( P 〉 O. 05 ) ; (3) After 36 months, 60 months, metastasis rates of basal-like type were 14. 0%, 36. 0%, higher than Luminal-type ( 3.1% , 20. 4% ) and HER-2 over-expression type (6. 3% , 21.9% ) with statistically difference (P 〈 0.05 ) ; (4)After 60 mo, mortality of Basal-like type was 24. 0%, higher than Luminal-type ( 10. 2% ) and HER-2 over-expression type ( 15.6% ) ; Mortality of HER-2 overexpression was higher than Luminal type with statistically difference ( P 〈 0. 05 ). Conclusion Luminal is the most common type in Axillary lymph node-negative invasive breast cancer molecular typing. Patients with Basal-like type have poor prognosis, followed by HER-2 overexpression type.
出处 《中国肿瘤临床与康复》 2014年第12期1426-1429,共4页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 浸润性乳腺癌 腋窝淋巴结 分子分型 预后 Invasive breast neoplasms Axillary lymph node Molecular typing Prognosis
  • 相关文献

参考文献13

  • 1陈学东,钱立元,易剪梅,曹天柱.三阴乳腺癌雄激素受体表达与瘤体大小、淋巴转移的关系[J].中国普通外科杂志,2014,23(5):695-697. 被引量:9
  • 2Engstrom MJ,Opdahl S,Hagen AI,et al.Molecular subtypes,histopathological grade and survival in a historic cohort of breast cancer patients[J].Breast Cancer Res Treat,2013,140:463-473.
  • 3Goldhirsch A,Wood WC,Coates AS,et al.Strategies for subtypes-dealhag with the diversity of breast cancer:highlights of the St.gallen international expert consensus on the primary therapy of fatfly breast cancer 2011[J].Ann Oncol,2011,22:1736-1747.
  • 4Gamucci T,Vaccaro A,Ciancola F,et al.Recurrence risk ha small,node-negative,early breast cancer:a multicenter retrospective analysis[J].J Cancer Res Clin Oncol,2013,139:853-860.
  • 5Iwamoto T,Booser D,Valero V,et al.Estrogen receptor(ER)mRNA and ER-related gene expression in breast cancers that are1%to 10%ER-positive by immunohistochemistry[J].J Clin Oncol,2012,30:729-734.
  • 6邰艳红,耿明.浸润性乳腺癌的分子分型及相关治疗概况[J].诊断病理学杂志,2014,21(6):377-379. 被引量:5
  • 7Cadoo KA,Traina TA,King TA.Advances in molecular and clinical subtyping of breast cancer and their implications for therapy[J].Surg Oncol Clhl N Am,2013,22:823-840.
  • 8汤俊,赵涓涓,张军,张弘,刘黎明.乳腺癌分子亚型中细胞周期素D1的表达及其与雌、孕激素受体的关系[J].中华实验外科杂志,2014,31(5):968-970. 被引量:6
  • 9Caldarella A,Buzzoni C,Crocetti E,et al.Invasive breast cancer:a significant correlation between histological types and molecular subgroups[J].J Cancer Res Clin Oncol,2013,139:617-623.
  • 10Hayashi N,Niikura N,Yamauchi H,et al.Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer[J].Breast Cancer Res Treat,2013,137:523-531.

二级参考文献106

  • 1莫军,杨丽珍,李景,邢自良.化学发光法检测妇女血清睾酮及其临床应用[J].现代检验医学杂志,2007,22(2):105-106. 被引量:9
  • 2van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature, 2002, 415:530-536.
  • 3Sotiriou C, Neo SY, MeShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population based study. Proc Natl Acad Sci U S A, 2003, 100: 10393- 10398.
  • 4Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer, 2007, 109:25-32.
  • 5Jones C, Nonni AV, Fulford L, et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer, 2001, 85:422-427.
  • 6Cunningham JE, Butler WM. Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis. Breast Cancer Res Treat, 2004, 88 : 161-176.
  • 7Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006, 295:2492-2502.
  • 8Lohrisch C, Piccart M. An overview of HER2. Semin Oncol, 2001, 28(6 Suppl 18) :3-11.
  • 9Vicini FA, Recht A. Age at diagnosis and outcome for women with ductal carcinoma-in-situ of the breast: a critical review of the literature. J Clin Oncol, 2002, 20:2736-2744.
  • 10Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst, 2003, 95:1482-1485.

共引文献86

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部